About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our research group is focused on studying the pathophysiology of migraine and other primary headaches using preclinical, translational and clinical research.
Migraine will allow us to define the brain’s adaptive, sensory/cognitive functions, through genetics, epigenetics, neurophysiology, neuromolecular and neuroanatomical information with an interest in developing clinical therapeutic solutions, with the goal on having an impact on suffering and increasing the well-being.
PMID: 35166156 Journal: CEPHALALGIA Year: 2022 Reference: Cephalalgia. 2022 Jul;42(8):804-809. doi: 10.1177/03331024211068074. Epub 2022 Feb 15. Impact factor: 6.295 Publication type: Paper in international publication Authors: Pozo-Rosich, Patricia; de Lorenzo, Inigo; Garcia-Azorin, David; Layos-Romero, Almudena; Porta-Etessam, Jesus; Membrilla, Javier A; Caronna, Edoardo; Gonzalez-Martinez, Alicia; Mencia, Alvaro Sierra; Segura, Tomas et al. DOI: 10.1177/03331024211068074
PMID: 35716692 Journal: LANCET NEUROLOGY Year: 2022 Reference: Lancet Neurol. 2022 Jul;21(7):597-607. doi: 10.1016/S1474-4422(22)00185-5. Impact factor: 44.182 Publication type: Paper in international publication Authors: Lanteri-Minet, Michel; Pozo-Rosich, Patricia; Ettrup, Anders; Christoffersen, Cecilie Laurberg; Josiassen, Mette Krog; Phul, Ravinder; Sperling, Bjorn; Ashina, Messoud et al. DOI: 10.1016/S1474-4422(22)00185-5
PMID: 35791285 Journal: CEPHALALGIA Year: 2022 Reference: Cephalalgia. 2022 Jul 5:3331024221110102. doi: 10.1177/03331024221110102. Impact factor: 6.295 Publication type: Paper in international publication Authors: Steiner, Timothy J; Terwindt, Gisela M; Katsarava, Zaza; Pozo-Rosich, Patricia; Gantenbein, Andreas R; Roche, Sarah L; Dell'Agnello, Grazia; Tassorelli, Cristina et al. DOI: 10.1177/03331024221110102
PMID: 35815637 Journal: CEPHALALGIA Year: 2022 Reference: Cephalalgia. 2022 Jul 9:3331024221111772. doi: 10.1177/03331024221111772. Impact factor: 6.295 Publication type: Paper in international publication Authors: Pozo-Rosich, Patricia, Gallardo, Victor Jose, Caronna, Edoardo, Vila-Ballo, Adria, Marti-Marca, Angela, Cerda-Company, Xim, Ikumi, Nara et al. DOI: 10.1177/03331024221111772
PMID: 32917437 Journal: NEUROLOGIA Year: 2021 Reference: Neurologia. 2021 Apr;36(3):229-240. doi: 10.1016/j.nrl.2020.04.029. Epub 2020 Sep 9. Impact factor: Publication type: Review in international publication Authors: Belvis, R; Cuadrado, M L; Diaz-Insa, S; Gonzalez-Oria, C; Guerrero-Peral, A L; Huerta, M; Irimia, P; Lainez, J M; Latorre, G; Leira, R et al. DOI: 10.1016/j.nrl.2020.04.029
PMID: 33730441 Journal: EUROPEAN JOURNAL OF NEUROLOGY Year: 2021 Reference: Eur J Neurol. 2021 Jul;28(7):2378-2382. doi: 10.1111/ene.14828. Epub 2021 Apr 5. Impact factor: Publication type: Letter whit IF Authors: Alpuente, Alicia; Caronna, Edoardo; Gallardo, Victor J; Pozo-Rosich, Patricia; Torres-Ferrus, Marta et al. DOI: 10.1111/ene.14828
PMID: 32444176 Journal: NEUROLOGIA Year: 2021 Reference: Neurologia. 2021 Mar;36(2):176. doi: 10.1016/j.nrl.2020.01.005. Epub 2020 May 20. Impact factor: Publication type: Letter or abstract Authors: Gonzalez-Garcia, N; Pozo-Rosich, P et al. DOI: 10.1016/j.nrl.2020.01.005
PMID: 33522600 Journal: HEADACHE Year: 2021 Reference: Headache. 2021 Feb;61(2):385-386. doi: 10.1111/head.14059. Epub 2021 Feb 1. Impact factor: Publication type: Letter or abstract Authors: Caronna, Edoardo; Pozo-Rosich, Patricia et al. DOI: 10.1111/head.14059
PMID: 32056459 Journal: CEPHALALGIA Year: 2020 Reference: Cephalalgia. 2020 Jul;40(8):778-787. doi: 10.1177/0333102420906843. Epub 2020 Feb 14. Impact factor: 4.868 Publication type: Review in international publication Authors: Alpuente, Alicia, Tassorelli, Cristina, Diener, Hans-Christoph, Silberstein, Stephen D, Pozo-Rosich, Patricia et al. DOI: 10.1177/0333102420906843
Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.
On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.
The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.
